Clinical Trials Browser

Active not recruiting × pomalidomide × 90 days × Clear all

NCT04108195 2026-04-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT04667663 2026-04-13

CPD-DARA

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-04-13

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 2 FDA

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT02659930 2026-04-01

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Phase 1 Active not recruiting

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT04162210 2026-03-31

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT04835129 2026-03-27

IMPEDE

Phase 2 Active not recruiting

Multiple Myeloma

NCT04910568 2026-03-19

CAMMA 1

Phase 1 Active not recruiting

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Phase 1 Active not recruiting

Multiple Myeloma